{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:15:36Z","timestamp":1761862536024},"reference-count":0,"publisher":"American Diabetes Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Care"],"published-print":{"date-parts":[[2006,5,1]]},"DOI":"10.2337\/diacare.2951016","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T21:29:09Z","timestamp":1146086949000},"page":"1016-1023","source":"Crossref","is-referenced-by-count":6,"title":["Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (\u00a0\/\u00a0) Peroxisome Proliferator-Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: A double-blind, randomized, pioglitazone-comparative study"],"prefix":"10.2337","volume":"29","author":[{"given":"D. M.","family":"Kendall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","container-title":["Diabetes Care"],"original-title":[],"language":"en","deposited":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T20:04:20Z","timestamp":1428609860000},"score":1,"resource":{"primary":{"URL":"http:\/\/care.diabetesjournals.org\/cgi\/doi\/10.2337\/diacare.2951016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,1]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.2951016","relation":{},"ISSN":["0149-5992","0149-5992"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"0149-5992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,1]]}}}